Mortality-related resource utilization in the inpatient care of hypoplastic left heart syndrome

David A Danford1, Quentin Karels2, Aparna Kulkarni3

  • 1University of Nebraska Medical Center and Children's Hospital and Medical Center, 8200 Dodge St, Omaha, NE, 68114, USA. ddanford@childrensomaha.org.

Insights

Significant hospital resources are spent on hypoplastic left heart syndrome (HLHS) care without survival. A mortality-related resource utilization fraction (MRRUF) analysis highlights the need to optimize care for better outcomes.

Area of Science:

  • Pediatric Cardiology
  • Health Services Research

Background:

  • Quantifying resource utilization in congenital heart disease inpatient care is crucial.
  • Hypoplastic left heart syndrome (HLHS) represents a significant burden on healthcare resources.

Purpose of the Study:

  • To measure inpatient resource investment for HLHS survival.
  • To determine the mortality-related resource utilization fraction (MRRUF) in HLHS hospitalizations.

Main Methods:

  • Utilized the Pediatric Health Information System (PHIS) database (2004-2013).
  • Analyzed HLHS admissions (≤21 years old) from 43 children's hospitals.
  • Recorded length of stay (LOS) and billed charges (BC) for inpatient deaths versus survivors.

Main Results:

  • 11,122 HLHS admissions incurred 277,027 inpatient-days and $3.93 billion in BC.
  • 10.3% of patients (1145) died during hospitalization.
  • Non-survivors accounted for 16% of LOS and 21% of BC, with no significant year-to-year change.

Conclusions:

  • A substantial portion of HLHS inpatient care resources are expended on patients who do not survive.
  • Highlights the necessity for data-driven review of HLHS care practices.
  • Emphasizes the need to identify and modify approaches to improve survival rates and optimize resource allocation.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
641
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
765
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
429
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532